Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not to mention, HIV approval should be a slam-dunk, considering safety and efficacy on 800 patients, so there is an income-generating engine there, independent of CV, cancer, etc. Downside buffer......
I will....to add more....
The way that I look at this stock, the pps hovering in this price range is really irrelevant anyway (a few pennies either direction), as within the next few weeks/months, I believe that we will be at $1, or a multiple of the current pps (much more likely). That determination will largely be determined by making the trial data public, and the "market's" perception of that data. Good luck to all Longs.....
Of course, still plenty of risk here relative to the AMZN's of the world, but I like our prospects, and have stepped up to the plate myself.
I am hoping that "roadmap," and associated expected dates are close enough to prevent another dip as I am loaded up. With that said, if the opportunity presents, and fundamentals remain strong (short to mid-term), I will add additional shares, myself.
Scooter, I would like to hear: 1.) When stopped trial data is accumulated (presumably after Monday June 15th) how soon Nader is going to "release it to the world?" 2.) If/when the company anticipates signing a distributor agreement w/pharma partner? 3.) When is reasonable estimate for actual uplisting to occur? 4.) How is enrollment going in Mexico?
Rock, I agree with you, the more communication from management the better. I appreciate Nader, and feel that he is working his butt off. Believe me, I have owned a few biotech stocks, some for many years, where getting information out of management was like pulling teeth (actually, my current situation with ATHX).
Bob, we are on exactly the same page.
Bob, ok, perhaps, indirectly, he has influence, but as we have no idea what is going on, behind the scenes regarding the review of the paper, we DO know that Dr. Patterson has submitted several papers in his career (the first in 1993). Having said that, I am quite sure that he understands the process including the revisions, and the time that is consumed through that process. I am quite sure that he is not "sand-bagging.":(
Nader has already said that he AND Dr. Kelly exercised warrants to subsidize a payment due to Samsung BioLogics Co. Ltd. for "clinical and commercial manufacturing of Leronlimab"!!!!!
First of all he has no control of when his journal submission will be peer-reviewed. Zero influence on when. Second of all, he will reveal what data that Nader and/or the FDA will allow him to reveal during trials. Although he is not a CYDY employee, he is clearly being compensated in some way. He has made his scientific thoughts known through several interviews, including Dr. Yo. If you haven't noticed, Nader has been much more tight-lipped lately regarding research data, but other forward-moving actions suggest that the data is good. I am quite sure that if Nader wanted him there he would be there.
Dr. Patterson does not work for CYDY. He is a scientist that discovered some of the "special" attributes of Leronlimab, not previously recognized. He has told his story, through print, interviews and videos. He has nothing to do with the business side of the company. What do you want him to do?
That is TRULY an ignorant statement!
Amatuer17, in all fairness, the company was in a completely different situation in March 2019 (financially, as well as other relevant variables), and was only working toward HIV indication (there was no CV) at that time. If data results, from current trials, are as expected, approval will come WAY before 2021!
Scooter, you might consider ATHX next, or concurrent with CYDY investment. Not so much for CV, but for stroke indication which will play out by the end of this year. I believe will become SOC. If you follow up I won't be able to reply as I am in iHub purgatory limited to 1 post a day for a few more days due to Justdafactss, and the "balanced" moderation of this message board. :(
Guys, would someone share with me Nader's email address please?
"Black-ops," I agree with you on all points 100%!
Amateur, I don't agree at all with your statement, "If it was really good news only - he would have issued it." If whatever Nader was sitting on was truly not "newsworthy" (perhaps not confirmed) until late Friday night, the company DEFINITELY would NOT just issue it, buried on a Friday night on a holiday weekend. I don't care if they got FDA approval (unless FDA would have put out independent of the company, forcing Nader's hand).
Dieselpro, I don't agree at all. I am a shareholder of both, and if stroke trial data is strong with ATHX, which is expected to be based on previous trials, it will become SOC worldwide for that indication. Like many of these "CV" stocks, ATHX and CYDY was not a CV stock before the advent of CV. ATHX has been working on multi stem for stroke for 20 years.
Foo, assuming that there is no p.r. in the a.m. that is the subject of the C.
C., which is often the case.
Daemon, I don't agree, if Nader had bad news last night was the time to drop it going into a 3 day weekend. Additionally, his C.C.s are generally 2, 3 hours earlier in the day. There could have been logistical issues with scheduling all involved. We shall see.....
Pac, I feel that if it was devastating news Nader would have just released the the actual news after hours on a holiday weekend.
There is plenty to do in Vegas for all tastes, but I fear that the new rules will really put a damper on that experience.
CYDYWinning, I think that Nader is going 100 mph, and working around the clock as mentioned a month or so ago on a call. On top of that, if this C.C. has " meat," and a P.R. is released prior to the C.C. on Tuesday, the shorts could potentially get roasted. Nader is also well aware of this phenomenon. We shall see on Tuesday........
"Epon," Great find!!!!!
The fact that CYDY has the balls (data confidence) to pick a fight with the bully on the block speaks volumes!!!!!
They don't need Gilead's permission. They will get the drug. Gilead isn't going to give CYDY the bullets to the gun intended on being used on them.
Venture, that is a Given. Big business always has dirty laundry behind the scenes. It goes without saying.
"dude," That IS a factor, but there is plenty of upside here. Remember, this is not just a CV indication.
"Venture," "play fair?" Are you kidding me, there is no "fair." This is big $ here. NOTHING is out of the question.
"Venture," well hopefully, an FDA acceptance of application for Leronlimab's BLA and receipt of PDUFA date for HIV ind....
Bunny, good find!
Fsoalex, i am just going by what he said. I believe that the moderator read the question twice, and he definitely said "buyout."
Hopester, that S-3 was dated 04/30/2020, and has been discussed ad nauseam
Hopester, that filing, dated yesterday, had already been discussed over a week ago. That had nothing to do with today's action. C'mon, keep up....
Blane, I agree with you on everything other than I DO think that Nader understood the question about buyout. Obviously, if uplisting is part of the master plan they will continue to pursue. Until/unless they got close to actually doing a buyout then they would shift gears; otherwise, stick with the plan unless one is sure that another plan is imminent.
"Breeze," NO! NONE of them are "surpassing Leronlimab." To paraphrase Dr. Patterson he said there was no other drug in the world like Leronlimab.
Pctwst, I think, perhaps, some were expecting more anecdotal cases, or some other news that had not yet been presented. It was a very good call, just not "headline-worthy." Uplisting comments were interesting, everyone still very "high" on Leronlimab, no "chinks in the armor" reported. Perhaps a bit more "professional" discussing trial data, rather than anecdotal information, that is expected to lead to our eventual success. All in all, very good.
Pctwst, there was nothing negative said, whatsoever, just nothing positive that was earth-shattering that we didn't already know. Couple that with a 500 point down Dow day.....
"Diesel," I can confirm that as was exactly what Nader said......Additionally, to paraphrase, he also said "We (Shareholders) will hear something in the next couple of weeks......